Madrigal Pharmaceuticals, Inc. Dividend History (MDGL)
Madrigal Pharmaceuticals, Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic, and liver diseases. Founded in 2011, the company is led by CEO Paul Friedman, M.D. Madrigal is notably working on therapies targeting non-alcoholic steatohepatitis (NASH) with lead product candidates like resmetirom, aimed at treating patients with this liver condition. The company is headquartered in West Conshohocken, Pennsylvania. While still in the pre-revenue stage due to its focus on drug development, Madrigal's work is highly anticipated in the pharmaceutical industry, given the significant need for effective NASH treatments.
Apple Inc.
Microsoft Corporation
Johnson & Johnson
Procter & Gamble Co.
Coca-Cola Co.
PepsiCo, Inc.
Exxon Mobil Corporation
Verizon Communications Inc.
AT&T Inc.
Chevron Corporation
Madrigal Pharmaceuticals has launched a new drug, Rezdiffra, which is the only approved treatment for metabolic-associated steatohepatitis (MASH) in patients with moderate to advanced liver fibrosis. The company's revenue is growing rapidly, and it has a strong cash position, making it a promising long-term investment despite potential competition from Novo Nordisk.
The Motley Fool · Published on Sun Nov 10 2024
Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.
Benzinga · Published on Sun Nov 03 2024
Viking Therapeutics, a clinical-stage biotech company, has multiple promising drug candidates in its pipeline, including a potential weight loss drug and a treatment for a rare neurodegenerative condition. The company's strong financial position and diverse portfolio make it an attractive investment opportunity for long-term investors, despite the inherent risks of the biotech industry.
The Motley Fool · Published on Thu Oct 31 2024